| Bioactivity | Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension[1][2][3]. |
| Invitro | l-Moprolol 是一种 β 阻断剂的 l-对映体，具有低负性肌力活性和轻度内在拟交感神经活性，可有效用于全身性高血压研究。在原发性开角型青光眼 (POAG) 或高眼压 (OHT) 模型中，局部应用l-Moprolol 可与噻洛尔一样有效地降低眼压 (IOP)，由于其对支气管肌肉缺乏活性，已成为抑制青光眼的一种很有前景的化合物[3]。 |
| Name | Moprolol |
| CAS | 5741-22-0 |
| Formula | C13H21NO3 |
| Molar Mass | 239.31 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Borowiecki P, et al. Development of a novel chemoenzymatic route to enantiomerically enriched β-adrenolytic agents. A case study toward propranolol, alprenolol, pindolol, carazolol, moprolol, and metoprolol. RSC Adv. 2022 Aug 10;12(34):22150-22160. [2]. Liu J, et al. beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther. 2006 Jul;80(1):23-32. [3]. Rossetti L, et al. The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 1994 Nov;232(11):670-4. |